Filtered By:
Drug: Erbitux

This page shows you your search results in order of date.

Order by Relevance | Date

Total 44 results found since Jan 2013.

Depleting receptor tyrosine kinases EGFR and HER2 overcomes resistance to EGFR inhibitors in colorectal cancer
CONCLUSIONS: Our study shows that CRC resistance to EGFR inhibitors results primarily from the inability of the inhibitors to downregulate their target and that a PEPDG278D-based combination treatment overcomes the resistance.PMID:35650607 | DOI:10.1186/s13046-022-02389-z
Source: Cell Research - June 1, 2022 Category: Cytology Authors: Lu Yang Arup Bhattacharya Yun Li Sandra Sexton Xiang Ling Fengzhi Li Yuesheng Zhang Source Type: research

Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells
Toxicol Appl Pharmacol. 2022 Mar 18:115989. doi: 10.1016/j.taap.2022.115989. Online ahead of print.ABSTRACTDue to recent advances in the field of small molecule-based drugs, designing an efficient siRNA delivery system seems essential. Here, modified sets of lipids conjugated with cell-penetrating TAT peptide, MMP2 enzyme-sensitive moiety, and cetuximab antibodies against the EGF receptor were synthesized, purified and verified on HPLC, TLC, SEM, and DLS analyses. Different cellular and molecular experiments were designed to evaluate the transfection efficiency, targeting properties, and functions, including cytotoxicity a...
Source: Toxicology and Applied Pharmacology - March 22, 2022 Category: Toxicology Authors: Mohsen Safaei Pegah Khosravian Sedighe Kazemi Sheykhshabani Gashtasb Mardani Fatemeh Elahian Seyed Abbas Mirzaei Source Type: research

Intracellular Co-delivery of native antibody and siRNA for combination therapy by using biodegradable silica nanocapsules
Biomaterials. 2022 Jan 17;281:121376. doi: 10.1016/j.biomaterials.2022.121376. Online ahead of print.ABSTRACTCombination therapy is a promising strategy for treating multidrug-resistant (MDR) cancers. Macromolecules such as antibodies and RNAs have been successfully used for targeted therapy owing to their high specificity. However, their application as therapeutics remains limited due to membrane impermeability and poor intracellular stability. Designing drug delivery systems capable of co-administering macromolecules is therefore crucial for advancing them as therapeutics for combination therapy. Herein, by using glutath...
Source: Biomaterials - January 22, 2022 Category: Materials Science Authors: Peiyan Yuan Fen Yang Si Si Liew Jiachang Yan Xiao Dong Jinfeng Wang Shubo Du Xin Mao Liqian Gao Shao Q Yao Source Type: research

Cetuximab-siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211041453. doi: 10.1177/15330338211041453.ABSTRACTDelivery of small-interfering RNA (siRNA) has been of great interest in the past decade for effective gene silencing. To overcome synthetic and regulatory challenges posed by nanoparticle-mediated siRNA delivery, antibody-siRNA conjugate (ARC) platform is emerging as a potential siRNA delivery system suitable for clinical translation. Herein, we have developed a delivery technology based on the ARC platform for stable delivery of siRNA called as Gelatin-Antibody Delivery System (GADS). In GADS, positively charged gelatin act...
Source: Technology in Cancer Research and Treatment - September 20, 2021 Category: Cancer & Oncology Authors: K Sreedurgalakshmi R Srikar K Harikrishnan Lakshmi Srinivasan Reena Rajkumari Source Type: research

MicroRNA-141-3p affected proliferation, chemosensitivity, migration and invasion of colorectal cancer cells by targeting EGFR.
Abstract Colorectal cancer (CRC) is one of the most often diagnosed cancers globally. MicroRNAs are small RNA molecules that play essential roles in tumorigenesis and progression of CRC. Here we evaluated the effects of miR-141-3p on growth, cetuximab sensitivity, migration and invasion of CRC cells. We found that miR-141-3p negatively regulated the proliferation, migration and invasion in CRC cells. In addition, miR-141-3p enhanced the cetuximab sensitivity of CRC cells by EGFR suppression. Moreover, miR-141-3p improved cetuximab-induced apoptosis in CRC cells. Furthermore, miR-141-3p altered the expression of E-...
Source: The International Journal of Biochemistry and Cell Biology - November 4, 2019 Category: Biochemistry Authors: Xing Y, Jing H, Zhang Y, Suo J, Qian M Tags: Int J Biochem Cell Biol Source Type: research

Combination of cetuximab with met inhibitor in control of cetuximab-resistant oral squamous cell carcinoma.
Conclusions: This study demonstrates that Met/HGF expression results in OSCC resistance to cetuximab and tumor recurrence after cetuximab therapy; thus, inhibition of Met/HGF activity could restore OSCC sensitivity to cetuximab. PMID: 31105843 [PubMed]
Source: American Journal of Translational Research - May 22, 2019 Category: Research Tags: Am J Transl Res Source Type: research

Cancers, Vol. 11, Pages 562: Dual Targeting of Y-Box Binding Protein-1 and Akt Inhibits Proliferation and Enhances the Chemosensitivity of Colorectal Cancer Cells
In this study, the effects of oncogenic mutated KRAS(G12V) and KRAS(G13D) on YB-1 phosphorylation were investigated in CRC cells. The effects of the inhibition of p90 ribosomal S6 kinase (RSK) on YB-1 phosphorylation, cell proliferation and survival were tested with and without treatment with 5-fluorouracil using pharmacological inhibitors and siRNA. YB-1 phosphorylation status and subcellular distribution in CRC patient tissues were determined by immunofluorescence staining and confocal microscopy. Endogenous expression of mutated KRAS(G13D) and conditional expression of KRAS(G12V) significantly stimulated YB-1 phosphoryl...
Source: Cancers - April 18, 2019 Category: Cancer & Oncology Authors: Maier Attenberger Tiwari Lettau Rebholz Fehrenbacher Schaller Gani Toulany Tags: Article Source Type: research

Molecular mechanisms of apoptosis and autophagy elicited by combined treatment with oridonin and cetuximab in laryngeal squamous cell carcinoma
AbstractCombined oridonin (ORI), a natural and safe kaurene diterpenoid isolated fromRabdosia rubescens, and cetuximab (Cet), an anti-EGFR monoclonal antibody, have been reported to exert synergistic anti-tumor effects against laryngeal squamous cell carcinoma (LSCC) both in vitro and in vivo by our group. In the present study, we further found that ORI/Cet treatment not only resulted in apoptosis but also induced autophagy. AMPK/mTOR signaling pathway was found to be involved in the activation of autophagy in ORI/Cet-treated LSCC cells, which is independent of p53 status. Additionally, chromatin immunoprecipitation (ChIP)...
Source: Apoptosis - November 14, 2018 Category: Molecular Biology Source Type: research

Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models.
Abstract Head and neck squamous cell carcinoma (HNSCC) currently only has one FDA-approved cancer intrinsic targeted therapy, the epidermal growth factor receptor (EGFR) inhibitor cetuximab, to which only approximately 10% of tumors are sensitive. In order to extend therapy options, we subjected patient-derived HNSCC cells to small-molecule inhibitor and siRNA screens, first, to find effective combination therapies with an EGFR inhibitor, and second, to determine a potential mechanistic basis for repurposing the FDA approved agents for HNSCC. The combinations of EGFR inhibitor with anaplastic lymphoma kinase (ALK)...
Source: Cancer Biology and Therapy - June 1, 2018 Category: Cancer & Oncology Authors: Ouyang X, Barling A, Lesch A, Tyner JW, Choonoo G, Zheng C, Jeng S, West TM, Clayburgh D, Courtneidge SA, McWeeney SK, Kulesz-Martin M Tags: Cancer Biol Ther Source Type: research